BioMarin Pharmaceutical Inc.
ABOUT
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with multiple commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
770 Lindaro Street
San Rafael, CA 94901
105 Digital Drive
Novato, CA 94949
San Rafael, CA 94901
105 Digital Drive
Novato, CA 94949
NEWS
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Scientific luminary and MacArthur Fellowship winner Kevin Eggan, Ph.D. will lead early-stage research at rare disease-focused BioMarin.
The agency indicated that they had completed the review cycle for the application but the application was not ready for approval in its current form.
With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.
BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS